Shares of PolarityTE PTE were flat in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 66.95% over the past year to ($0.39), which beat the estimate of ($0.52).
Revenue of $933,000 less by 36.31% from the same period last year, which missed the estimate of $1,570,000.
Looking Ahead
PolarityTE hasn't issued any earnings guidance for the time being.
PolarityTE hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 11, 2020
Time: 09:02 PM ET
Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1307552&tp_key=b1efa9a520
Recent Stock Performance
52-week high: $8.89
Company's 52-week low was at $0.78
Price action over last quarter: down 12.38%
Company Overview
PolarityTE Inc is a commercial-stage biotechnology and regenerative biomaterials company. Its focused on transforming the lives of patients by discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement or regeneration of skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.